(Q26826933)

F. De Vita

2

1 reference

J. Koskinas

3

1 reference

D. Semela

4

1 reference

P. Toniutto

5

1 reference

C. Verslype

6

1 reference

language of work or name

1 reference

April 2013

1 reference

1 reference

24 Suppl 2

1 reference

PubMed

page(s)

ii30-7

1 reference

PubMed

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

From randomized controlled trials to observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

The cancer biomarker problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055

inferred from DOI database lookup

7 January 2021

based on heuristic

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT055